Abstract
National Experience of the use of the highly selective RET tyrosine kinase inhibitor Selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid cancer: updated experience
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
